5 assets in Extrahepatic Bile Duct Adenocarcinoma

Therapeutic assets addressing Extrahepatic Bile Duct Adenocarcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Atezolizumab Extrahepatic Bile Duct Adenocarcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Cobimetinib Extrahepatic Bile Duct Adenocarcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Immunoglobulin G1, Anti-(Human Cd Antigen Cd27) (Human Monoclonal Cdx-1127 Clone 1F5 Heavy Chain), Disulfide With Human Monoclonal Cdx-1127 Clone 1F5 .Kappa.-Chain, Dimer Extrahepatic Bile Duct Adenocarcinoma	National Cancer Institute (NCI)	P2	CC (44)
Durvalumab Extrahepatic Bile Duct Adenocarcinoma	University of Southern California	P1	CC (43)
Guadecitabine Extrahepatic Bile Duct Adenocarcinoma	University of Southern California	P1	CC (43)